Alexis RIDEAU appointed CEO of DEINOVE
January 11, 2021 12:30 ET
|
Deinove
Alexis RIDEAU appointed CEO of DEINOVE Alexis RIDEAU, Deputy Chief Executive Officer of DEINOVE since May 2020, is now the Chief Executive Officer of the Company.Charles WOLER, who acted as...
Alexis RIDEAU est nommé Directeur Général de DEINOVE
January 11, 2021 12:30 ET
|
Deinove
Alexis RIDEAU est nommé Directeur Général de DEINOVE Alexis RIDEAU, Directeur Général Délégué de DEINOVE depuis mai 2020, est désormais Directeur Général de la SociétéCharles WOLER, qui a assuré...
Emission d’une 4ème tranche d'OCA de 1,5 m€
December 03, 2020 12:30 ET
|
Deinove
EMISSION D’UNE 4ème TRANCHE D'OCA DE 1,5 M€ DEINOVE renforce immédiatement sa trésorerie pour financer la poursuite de l’essai clinique de DNV3837 dans le traitement des infections...
Issuance of a 4th tranche of €1.5 million of notes convertible into new shares
December 03, 2020 12:30 ET
|
Deinove
ISSUANCE OF A 4th TRANCHE OF €1.5 MILLION OF NOTES CONVERTIBLE INTO NEW SHARES ·DEINOVE immediately strengthens its cash position to finance the ongoing clinical trial testing DNV3837 for the...
DEINOVE signe une licence d'évaluation et de développement technologique avec DSM
November 19, 2020 12:30 ET
|
Deinove
DEINOVE signe une licence d'évaluation et de développement technologique avec DSM DEINOVE (Euronext Growth Paris : ALDEI), société de biotechnologie française pionnière dans l’exploration et...
DEINOVE signs an Evaluation and Technology Development License with DSM
November 19, 2020 12:30 ET
|
Deinove
DEINOVE signs an Evaluation and Technology Development License with DSM DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company that pioneers the application of biodiversity from the...
DEINOVE selected for a presentation at the C Diff Foundation annual Conference 2020
November 12, 2020 12:30 ET
|
Deinove
DEINOVE selected for a presentation at the C Diff Foundation annual Conference 2020 ·Yannick Pletan to present the DNV3837 mechanism of action, key features of the antibiotic candidate and the...
2020 Half-year results: Stronger financial position and research programs moving forward despite the international context
October 01, 2020 12:30 ET
|
Deinove
2020 Half-year results: Stronger financial position and research programs moving forward despite the international context Clinical program for the antibiotic candidate DNV3837 continues, with the...
DNV3837 antibiotic candidate: the Phase II trial continues in the US
July 15, 2020 12:30 ET
|
Deinove
DNV3837 antibiotic candidate: the Phase II trial continues in the United States, despite a disrupted context due to the COVID-19 outbreak DEINOVE (Euronext Growth Paris: ALDEI), a French biotech...
Alexis RIDEAU appointed Chief Executive Officer of DEINOVE with the ambition to strengthen the Company's strategy for innovation and partnerships
May 04, 2020 01:32 ET
|
Deinove
Alexis RIDEAU has recognized experience in the development, negotiation and implementation of strategic partnerships in the life sciences field, particularly in microbiology applied to health and...